Will R&D Suffer When Pfizer, Allergan Merge?
This article was originally published in Scrip
Executive Summary
Reducing Pfizer Inc.'s tax rate is undeniably the top reason for the company's pending $160bn merger with Allergan PLC, but without pharmaceutical products and research programs that could significantly boost revenue growth, it seems unlikely that Pfizer would invest billions of dollars and invoke the ire of US politicians and regulators by completing a tax inversion.